SynsoryBio
Active"If-then" conditional logic for protein drugs
About
SynsoryBio is creating next generation, protein therapeutics that sense where they are in the body and only activate at diseased tissue. This technology platform has the potential to expand the therapeutic window of highly potent drugs and apply to many diseases such as cancer and autoimmune disorders.
Founders · 2
I am a PhD and inventor in the fields of synthetic biology and protein engineering. I got my PhD from Boston University, spent time as a visiting graduate student in George Church's lab at Harvard, and worked in various biotech startups. In my free time, I like to spend time with friends and family, ride bikes, go hiking, and occasionally paint.
I’m a co-founder of SynsoryBio, where we are creating therapeutics that sense-and-respond to disease. I have a background in synthetic biology and protein engineering with a PhD in Biomedical Engineering.
Launch
Our immune system acts locally to combat disease, why don’t our medicines?
SynsoryBio engineers protein therapeutics that conditionally activate only at disease sites by sensing specific biomarkers, applying this to clinically tested cancer immunotherapies to improve safety and efficacy. They aim to partner with immunologists or oncologists and seek collaborations.
From the original launch (Feb 2024) — may be outdated.
Related startups
AI Hypothesis Engine for Molecular Discovery
Agentic AI platform for Pharma GTM teams
